OTCMKTS:CRPOF Ceapro (CRPOF) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free CRPOF Stock Alerts $0.18 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.18▼$0.1850-Day Range$0.12▼$0.1852-Week Range$0.11▼$0.44VolumeN/AAverage Volume500 shsMarket Capitalization$14.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Ceapro alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Ceapro Stock (OTCMKTS:CRPOF)Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.Read More CRPOF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRPOF Stock News HeadlinesMarch 28, 2024 | finanznachrichten.deAeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | globenewswire.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 12, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsFebruary 26, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 23, 2024 | globenewswire.comCeapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base BusinessFebruary 15, 2024 | globenewswire.comCeapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna ZentarisDecember 13, 2023 | finance.yahoo.comCeapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based DiseasesApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.November 29, 2023 | msn.comCeapro GAAP EPS of -C$0.01, revenue of C$2.62MNovember 7, 2023 | finance.yahoo.comCeapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) TechnologyJuly 18, 2023 | finance.yahoo.comCeapro Announces Next Phase of Research Collaboration with the Angiogenesis FoundationJune 7, 2023 | finanznachrichten.deCeapro Inc.: Ceapro Announces Results of 2023 Shareholders' MeetingJune 7, 2023 | finance.yahoo.comCeapro Announces Results of 2023 Shareholders’ MeetingApril 27, 2023 | finance.yahoo.comCeapro Inc. Appoints Michel Regnier as Senior Vice President, Technical OperationsApril 26, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Tuesday (CZO)April 25, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc flat on Monday (CZO)April 13, 2023 | theglobeandmail.comClosing Bell: Ceapro Inc down on Thursday (CZO)March 23, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with McMaster University to be Presented at the 2023 American Thoracic Society (ATS) International ConferenceMarch 14, 2023 | finance.yahoo.comCeapro Inc. (CRPOF) Stock Historical Prices & Data - Yahoo FinanceMarch 8, 2023 | finance.yahoo.comCeapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American SocietyFebruary 21, 2023 | finance.yahoo.comCeapro Inc. Recognized as a Top 50 TSX Venture Exchange CompanyJanuary 10, 2023 | finance.yahoo.comCeapro to Present at the Virtual Investor 2023 Companies to Watch EventDecember 22, 2022 | msn.comCeapro receives approval to begin human trial for anti-inflammatory drugDecember 22, 2022 | technews.tmcnet.comCeapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide TabletsNovember 9, 2022 | finance.yahoo.comCeapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational HighlightsNovember 7, 2022 | finance.yahoo.comCeapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical MarketsSee More Headlines Receive CRPOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ceapro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Next Earnings (Estimated)5/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CRPOF CUSIPN/A CIKN/A Webwww.ceapro.com Phone(780) 421-4555Fax780-421-1320EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.38 million Net Margins-24.95% Pretax Margin-31.44% Return on Equity-8.91% Return on Assets-7.81% Debt Debt-to-Equity RatioN/A Current Ratio11.00 Quick Ratio7.72 Sales & Book Value Annual Sales$14.49 million Price / Sales1.00 Cash Flow$0.06 per share Price / Cash Flow2.97 Book Value$0.32 per share Price / Book0.58Miscellaneous Outstanding Shares78,290,000Free FloatN/AMarket Cap$14.44 million OptionableNot Optionable Beta1.53 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Gilles R. Gagnon ICD.D (Age 70)M.B.A., M.Sc., CEO, President & Director Comp: $409.89kMs. Stacy Prefontaine C.A.CPA, CA, CPA, CFO & Corporate SecretaryDr. Bernhard SeifriedSenior Director of Research & TechnologyMr. Michel Regnier P. Eng.Senior Vice President of Technical OperationsKey CompetitorsEdesa BiotechNASDAQ:EDSAOncotelic TherapeuticsOTCMKTS:OTLCABVC BioPharmaNASDAQ:ABVCNeuroBo PharmaceuticalsNASDAQ:NRBOTraws PharmaNASDAQ:TRAWView All Competitors CRPOF Stock Analysis - Frequently Asked Questions How have CRPOF shares performed in 2024? Ceapro's stock was trading at $0.1652 at the beginning of the year. Since then, CRPOF shares have increased by 11.7% and is now trading at $0.1845. View the best growth stocks for 2024 here. When is Ceapro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our CRPOF earnings forecast. How do I buy shares of Ceapro? Shares of CRPOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRPOF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ceapro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
